Table 3.
Baseline clinical characteristics of patients with and without recurrence after first TACE
| Variables | Overall (N=149) | Recurrence (N=93) | No recurrence (N=56) | P value |
|---|---|---|---|---|
| Age (years)* | 62.5 (54.6-71.9) | 62.5 (54.9-70.3) | 62.5 (54.5-72.8) | 0.697 |
| Gender (male, %) | 105 (70.5) | 63 (67.7) | 42 (75.0) | 0.347 |
| Body weight loss, n (%) | 11 (6.8) | 5 (5.4) | 6 (10.7) | 0.227 |
| Virus/Alcoholic/Cryptogenic, n (%) | 131/12/6 (87.9/8.1/4.0) | 84/5/4 (90.3/5.4/4.3) | 47/7/2 (83.9/12.5/3.6) | 0.300 |
| Anti-viral medication use, n (%) | 55 (42.3) | 37 (44.6) | 18 (38.3) | 0.486 |
| BMI (Kg/m2)* | 25.2 (22.9-28.6) | 25.2 (23.8-28.6) | 25.2 (22.6-28.9) | 0.256 |
| DM, n (%) | 45 (30.2) | 34 (36.6) | 11 (19.6) | 0.029 |
| CTP class A/B, n (%) | 131/18 (87.9/12.1) | 85/8 (91.4/8.6) | 46/10 (82.1/17.9) | 0.093 |
| BCLC stage 0/A/B/C, n (%) | 22/62/18/47 (14.8/41.6/12.1/31.5) | 12/38/12/31 (12.9/40.9/12.9/33.3) | 10/24/6/16 (17.9/42.9/10.7/28.6) | 0.800 |
| AST (U/L)* | 48 (33-69) | 49 (37-70) | 41 (29-69) | 0.034 |
| ALT (U/L)* | 37 (25-58) | 37 (26-71) | 30 (23-44) | 0.006 |
| AFP (ng/mL)* | 18 (7-171) | 40 (11-267) | 16 (6-502) | 0.037 |
| Platelet (1000/μL)* | 94 (65-144) | 100 (65-138) | 89 (64-134) | 0.046 |
| Creatinine (mg/dL)* | 0.73 (0.59-0.92) | 0.75 (0.58-0.92) | 0.72 (0.59-0.87) | 0.952 |
| Sodium (mEq/L)* | 141 (138-142) | 141 (139-143) | 141 (138-142) | 0.581 |
| Tumor numbers, n (%) 1/2&3/>3 | 94/42/13 (63.1/28.2/8.7) | 56/29/8 (60.2/31.2/8.6) | 38/13/5 (67.9/23.2/8.9) | 0.573 |
| Target lesion size (cm)* | 2.4 (1.6-3.5) | 2.6 (1.7-3.6) | 2.0 (1.5-3.5) | 0.044 |
| Within up-to-seven criteria, n (%) | 136 (91.3) | 84 (90.3) | 52 (92.9) | 0.595 |
| Tumor extent unilobar, n (%) | 122 (81.9) | 74 (79.6) | 48 (85.7) | 0.346 |
| Macrovascular invasion, n (%) | 10 (6.7) | 8 (8.6) | 2 (3.6) | 0.235 |
| Fever, n (%) | 30 (20.1) | 17 (18.3) | 13 (23.2) | 0.467 |
| Mortality, n (%) | 48 (32.2) | 39 (41.9) | 9 (16.1) | 0.001 |
| Disease free interval (months)* | 35.8 (26.1-44.9) | 13.5 (8.3-19.7) | 35.0 (24.1-43.7) | <0.001 |
*
Demonstrated as median (IQR).
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; CTP, Child-Turcotte-Pugh; DM, Diabetes mellitus; INR, international normalized ratio; NLR, neutrophil-lymphocyte ratio; TACE, transarterial chemoembolization.